Cargando…

Hypermanganesemia with Dystonia Type 2: A Potentially Treatable Neurodegenerative Disorder: A Case Series in a Tertiary University Hospital

Importance: Hypermanganesemia with dystonia type 2 is a rare autosomal recessive neurodegenerative disorder characterized by the loss of previously acquired milestones, dystonia, parkinsonian features, a high serum manganese level, and characteristic neuroimaging findings such as bilateral and symme...

Descripción completa

Detalles Bibliográficos
Autores principales: Alhasan, Khalid A., Alshuaibi, Walaa, Hamad, Muddathir H., Salim, Suha, Jamjoom, Dima Z., Alhashim, Aqeela H., AlGhamdi, Malak Ali, Kentab, Amal Y., Bashiri, Fahad A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497897/
https://www.ncbi.nlm.nih.gov/pubmed/36138644
http://dx.doi.org/10.3390/children9091335
_version_ 1784794621275013120
author Alhasan, Khalid A.
Alshuaibi, Walaa
Hamad, Muddathir H.
Salim, Suha
Jamjoom, Dima Z.
Alhashim, Aqeela H.
AlGhamdi, Malak Ali
Kentab, Amal Y.
Bashiri, Fahad A.
author_facet Alhasan, Khalid A.
Alshuaibi, Walaa
Hamad, Muddathir H.
Salim, Suha
Jamjoom, Dima Z.
Alhashim, Aqeela H.
AlGhamdi, Malak Ali
Kentab, Amal Y.
Bashiri, Fahad A.
author_sort Alhasan, Khalid A.
collection PubMed
description Importance: Hypermanganesemia with dystonia type 2 is a rare autosomal recessive neurodegenerative disorder characterized by the loss of previously acquired milestones, dystonia, parkinsonian features, a high serum manganese level, and characteristic neuroimaging findings such as bilateral and symmetrically increased T1 and decreased T2/fluid-attenuated inversion recovery signal intensity in the basal ganglia. This condition is secondary to a mutation in the SLC39A14 gene. Objective: To present a series of three cases of hypermanganesemia with dystonia type 2, which was genetically confirmed secondary to a mutation in the SLC39A14 gene, and to describe the treatment and clinical course in these cases. Design: A retrospective case series. Setting: University, Tertiary hospital. Participants: Three unrelated pediatric patients with hypermanganesemia with dystonia type 2, genetically confirmed to be secondary to a mutation in the SLC39A14 gene. Exposures: Chelation therapy using calcium disodium edetate. Main outcome(s) and measure(s): The response to chelation therapy based on clinical improvements in motor and cognition developments. Results: All three patients were started on chelation therapy using calcium disodium edetate, and two of them showed an improvement in their clinical course. The chelation therapy could alter the course of the disease and prevent deterioration in the clinical setting. Conclusions and Relevance: Early diagnosis and intervention with chelating agents, such as calcium disodium edetate, will help change the outcome in patients with hypermanganesemia with dystonia type 2. This finding highlights the importance of early diagnosis and treatment in improving the outcomes of patients with treatable neurodegenerative disorders.
format Online
Article
Text
id pubmed-9497897
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94978972022-09-23 Hypermanganesemia with Dystonia Type 2: A Potentially Treatable Neurodegenerative Disorder: A Case Series in a Tertiary University Hospital Alhasan, Khalid A. Alshuaibi, Walaa Hamad, Muddathir H. Salim, Suha Jamjoom, Dima Z. Alhashim, Aqeela H. AlGhamdi, Malak Ali Kentab, Amal Y. Bashiri, Fahad A. Children (Basel) Article Importance: Hypermanganesemia with dystonia type 2 is a rare autosomal recessive neurodegenerative disorder characterized by the loss of previously acquired milestones, dystonia, parkinsonian features, a high serum manganese level, and characteristic neuroimaging findings such as bilateral and symmetrically increased T1 and decreased T2/fluid-attenuated inversion recovery signal intensity in the basal ganglia. This condition is secondary to a mutation in the SLC39A14 gene. Objective: To present a series of three cases of hypermanganesemia with dystonia type 2, which was genetically confirmed secondary to a mutation in the SLC39A14 gene, and to describe the treatment and clinical course in these cases. Design: A retrospective case series. Setting: University, Tertiary hospital. Participants: Three unrelated pediatric patients with hypermanganesemia with dystonia type 2, genetically confirmed to be secondary to a mutation in the SLC39A14 gene. Exposures: Chelation therapy using calcium disodium edetate. Main outcome(s) and measure(s): The response to chelation therapy based on clinical improvements in motor and cognition developments. Results: All three patients were started on chelation therapy using calcium disodium edetate, and two of them showed an improvement in their clinical course. The chelation therapy could alter the course of the disease and prevent deterioration in the clinical setting. Conclusions and Relevance: Early diagnosis and intervention with chelating agents, such as calcium disodium edetate, will help change the outcome in patients with hypermanganesemia with dystonia type 2. This finding highlights the importance of early diagnosis and treatment in improving the outcomes of patients with treatable neurodegenerative disorders. MDPI 2022-09-01 /pmc/articles/PMC9497897/ /pubmed/36138644 http://dx.doi.org/10.3390/children9091335 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Alhasan, Khalid A.
Alshuaibi, Walaa
Hamad, Muddathir H.
Salim, Suha
Jamjoom, Dima Z.
Alhashim, Aqeela H.
AlGhamdi, Malak Ali
Kentab, Amal Y.
Bashiri, Fahad A.
Hypermanganesemia with Dystonia Type 2: A Potentially Treatable Neurodegenerative Disorder: A Case Series in a Tertiary University Hospital
title Hypermanganesemia with Dystonia Type 2: A Potentially Treatable Neurodegenerative Disorder: A Case Series in a Tertiary University Hospital
title_full Hypermanganesemia with Dystonia Type 2: A Potentially Treatable Neurodegenerative Disorder: A Case Series in a Tertiary University Hospital
title_fullStr Hypermanganesemia with Dystonia Type 2: A Potentially Treatable Neurodegenerative Disorder: A Case Series in a Tertiary University Hospital
title_full_unstemmed Hypermanganesemia with Dystonia Type 2: A Potentially Treatable Neurodegenerative Disorder: A Case Series in a Tertiary University Hospital
title_short Hypermanganesemia with Dystonia Type 2: A Potentially Treatable Neurodegenerative Disorder: A Case Series in a Tertiary University Hospital
title_sort hypermanganesemia with dystonia type 2: a potentially treatable neurodegenerative disorder: a case series in a tertiary university hospital
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497897/
https://www.ncbi.nlm.nih.gov/pubmed/36138644
http://dx.doi.org/10.3390/children9091335
work_keys_str_mv AT alhasankhalida hypermanganesemiawithdystoniatype2apotentiallytreatableneurodegenerativedisorderacaseseriesinatertiaryuniversityhospital
AT alshuaibiwalaa hypermanganesemiawithdystoniatype2apotentiallytreatableneurodegenerativedisorderacaseseriesinatertiaryuniversityhospital
AT hamadmuddathirh hypermanganesemiawithdystoniatype2apotentiallytreatableneurodegenerativedisorderacaseseriesinatertiaryuniversityhospital
AT salimsuha hypermanganesemiawithdystoniatype2apotentiallytreatableneurodegenerativedisorderacaseseriesinatertiaryuniversityhospital
AT jamjoomdimaz hypermanganesemiawithdystoniatype2apotentiallytreatableneurodegenerativedisorderacaseseriesinatertiaryuniversityhospital
AT alhashimaqeelah hypermanganesemiawithdystoniatype2apotentiallytreatableneurodegenerativedisorderacaseseriesinatertiaryuniversityhospital
AT alghamdimalakali hypermanganesemiawithdystoniatype2apotentiallytreatableneurodegenerativedisorderacaseseriesinatertiaryuniversityhospital
AT kentabamaly hypermanganesemiawithdystoniatype2apotentiallytreatableneurodegenerativedisorderacaseseriesinatertiaryuniversityhospital
AT bashirifahada hypermanganesemiawithdystoniatype2apotentiallytreatableneurodegenerativedisorderacaseseriesinatertiaryuniversityhospital